Efficacy and Safety of High-Density Lipoprotein/Apolipoprotein A1 Replacement Therapy in Humans and Mice With Atherosclerosis: A Systematic Review and Meta-Analysis
Background: Although elevation of HDL-C levels by pharmaceutical drugs have no benefit of cardiovascular endpoint, the effect of high-density lipoprotein/apolipoprotein A1 (HDL/apoA-1) replacement therapy on atherosclerosis is controversial. The current meta-analysis analyzed the effects of HDL/apoA...
Автори: | Ayiguli Abudukeremu, Canxia Huang, Hongwei Li, Runlu Sun, Xiao Liu, Xiaoying Wu, Xiangkun Xie, Jingjing Huang, Jie Zhang, Jinlan Bao, Yuling Zhang |
---|---|
Формат: | Стаття |
Мова: | English |
Опубліковано: |
Frontiers Media S.A.
2021-08-01
|
Серія: | Frontiers in Cardiovascular Medicine |
Предмети: | |
Онлайн доступ: | https://www.frontiersin.org/articles/10.3389/fcvm.2021.700233/full |
Схожі ресурси
Схожі ресурси
-
Proteomic and functional analysis of HDL subclasses in humans and rats: a proof-of-concept study
за авторством: Canxia Huang, та інші
Опубліковано: (2023-06-01) -
A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids
за авторством: Mohamad Navab, та інші
Опубліковано: (2009-08-01) -
Association of human apolipoprotein E with lipoproteins secreted by transfected McA RH7777 cells
за авторством: Catherine A. Reardon, та інші
Опубліковано: (1998-07-01) -
Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide <span style="font-variant: small-caps">d</span>-[113–122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice
за авторством: Andrea Rivas-Urbina, та інші
Опубліковано: (2020-05-01) -
Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research
за авторством: Karin Kornmueller, та інші
Опубліковано: (2019-08-01)